Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H29N9O3 |
Molecular Weight | 515.567 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCCC[C@H](N)C(=O)NC1=CC=C(C=C1)C(=O)CN2C3=CC=CC=C3N=C2C4=NON=C4NCCC#N
InChI
InChIKey=NIPZLALJRAHABJ-IBGZPJMESA-N
InChI=1S/C26H29N9O3/c27-13-4-3-6-19(29)26(37)31-18-11-9-17(10-12-18)22(36)16-35-21-8-2-1-7-20(21)32-25(35)23-24(34-38-33-23)30-15-5-14-28/h1-2,7-12,19H,3-6,13,15-16,27,29H2,(H,30,34)(H,31,37)/t19-/m0/s1
Lisavanbulin, also known as BAL-101553, a prodrug of the molecule BAL-27862 with potential antitumor activity. BAL-27862 binds to tubulin, prevents tubulin polymerization, destabilizes microtubules, arrests tumor cell proliferation, and induces cell death in cancer cells. Lisavanbulin participated in phase II clinical trials for the treatment of advanced solid tumors. Besides, the drug participates in a 1/2a clinical study in patients with recurrent glioblastoma and in patients with platinum-resistant or refractory ovarian cancer. In this study, will be characterized the safety and tolerability and to obtain efficacy data in these selected cancer types.
Originator
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C25974
Created by
admin on Sat Dec 16 11:30:52 GMT 2023 , Edited by admin on Sat Dec 16 11:30:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
828321
Created by
admin on Sat Dec 16 11:30:52 GMT 2023 , Edited by admin on Sat Dec 16 11:30:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB15224
Created by
admin on Sat Dec 16 11:30:52 GMT 2023 , Edited by admin on Sat Dec 16 11:30:52 GMT 2023
|
PRIMARY | |||
|
5PT0QP06X5
Created by
admin on Sat Dec 16 11:30:52 GMT 2023 , Edited by admin on Sat Dec 16 11:30:52 GMT 2023
|
PRIMARY | |||
|
C97664
Created by
admin on Sat Dec 16 11:30:52 GMT 2023 , Edited by admin on Sat Dec 16 11:30:52 GMT 2023
|
PRIMARY | |||
|
100000174635
Created by
admin on Sat Dec 16 11:30:52 GMT 2023 , Edited by admin on Sat Dec 16 11:30:52 GMT 2023
|
PRIMARY | |||
|
1263384-43-5
Created by
admin on Sat Dec 16 11:30:52 GMT 2023 , Edited by admin on Sat Dec 16 11:30:52 GMT 2023
|
PRIMARY | |||
|
FG-141
Created by
admin on Sat Dec 16 11:30:52 GMT 2023 , Edited by admin on Sat Dec 16 11:30:52 GMT 2023
|
PRIMARY | |||
|
10401
Created by
admin on Sat Dec 16 11:30:52 GMT 2023 , Edited by admin on Sat Dec 16 11:30:52 GMT 2023
|
PRIMARY | |||
|
45259014
Created by
admin on Sat Dec 16 11:30:52 GMT 2023 , Edited by admin on Sat Dec 16 11:30:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE ACTIVE (PRODRUG)
SALT/SOLVATE (PARENT)